Purpose While in the era of precision medicine, the right drug for each patient is selected
based on molecular tumor characteristics, most novel oral targeted anticancer agents are …

Background Oral targeted therapies show a high pharmacokinetic (PK) interpatient
variability. Even though exposure has been positively correlated with efficacy for many of …

New oral targeted anticancer therapies are revolutionizing cancer treatment by transforming
previously deadly malignancies into chronically manageable conditions. Nevertheless, drug …

Fixed dosing of oral targeted therapies is inadequate in the era of precision medicine.
Personalized dosing, based on pharmacokinetic (PK) exposure, known as therapeutic drug …

Purpose This review provides an overview of the current challenges in oral targeted
antineoplastic drug (OAD) dosing and outlines the unexploited value of therapeutic drug …

Background: Oral anticancer drugs show a high interpatient variability in pharmacokinetics
(PK), leading to large differences in drug exposure. For many of these drugs, exposure has …

The prerequisites for the successful implementation of therapeutic drug monitoring (TDM)
include high inter-subject variation, low inter-occasion variation, narrow therapeutic index …

Generally, licensed drug‐dosing recommendations for chemotherapy are based on results
from clinical trials in which subjects are usually of relatively normal body size, middle‐aged …

Therapeutic drug monitoring (TDM) can be defined as the measurement of drug in biological
samples to individualise treatment by adapting drug dose to improve efficacy and/or reduce …

Background Therapeutic drug monitoring (TDM)–performing dose adjustments based on
measured drug levels and established pharmacokinetic (PK) targets–could optimise …